Targeting AKR1B1 inhibits metabolic reprogramming to reverse systemic therapy resistance in hepatocellular carcinoma

Targeting AKR1B1 inhibits metabolic reprogramming to reverse systemic therapy resistance in hepatocellular carcinoma

Abstract Hepatocellular carcinoma (HCC) is a leading cause of cancer-related mortality, and resistance to systemic therapies remains a significant clinical challenge. This study investigated the mechanisms by which metabolic reprogramming contributes to systemic treatment resistance in HCC. We estab...

Full description

Saved in:
Bibliographic Details
Main Authors: Qi Wang, Juan Liu, Ming Yang, Jun Zhou, Yaxuan Li, Jingjing Zheng, Hao Jia, Shuhua Yue, Yinpeng Le, Yuxin Su, Wenrui Ma, Ni An, Yunfang Wang, Jiahong Dong
Format: Article
Language:English
Published: Nature Publishing Group 2025-08-01
Series:Signal Transduction and Targeted Therapy
Online Access:https://doi.org/10.1038/s41392-025-02321-9
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items

Similar Items